Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Can Completion Lymph Node Dissection Be Avoided for a Positive Sentinel Node in Melanoma?

Can Completion Lymph Node Dissection Be Avoided for a Positive Sentinel Node in Melanoma? Annals of Surgical Oncology 14(9):2437–2439 DOI: 10.1245/s10434-007-9474-9 Melanomas Can Completion Lymph Node Dissection Be Avoided for a Positive Sentinel Node in Melanoma? 1 1 2 Donald L. Morton, MD, Randall P. Scheri, MD, and Charles M. Balch, MD John Wayne Cancer Institute, Saint Johns Health Center, Santa Monica, CA, USA Johns Hopkins Medical Institutions, Baltimore, MD, USA Sentinel node biopsy (SNB) in melanoma was with hematoxyin and eosin (H&E) and with immu- developed as a minimally invasive technique to nohistochemistry using antibodies to S-100 and identify the 20% of patients who have occult lymph HMB-45. NSNs were bivalved and examined only by node metastases and therefore could benefit from H&E, which probably led to underestimation of the completion lymph node dissection (CLND). Recently incidence of NSN metastasis. Data on patient published interim results from the first Multicenter demographics and primary tumor pathological fea- Selective Lymphadenectomy Trial (MSLT-I) have tures were collected, and the SNs were microana- validated the accuracy and reliability of SNB in tomically staged for zone of metastatic involvement, 1,2 melanoma. Interestingly, results revealed that number of tumor-involved zones, size of metastases, nearly 80–90% of patients who underwent CLND and number of metastatic foci. Of 127 patients http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Surgical Oncology Springer Journals

Can Completion Lymph Node Dissection Be Avoided for a Positive Sentinel Node in Melanoma?

Download PDF
3 pages

Loading next page...
 
/lp/springer-journals/can-completion-lymph-node-dissection-be-avoided-for-a-positive-SKy7qmD84N

References (17)

Publisher
Springer Journals
Copyright
Copyright © 2007 by Society of Surgical Oncology
Subject
Medicine & Public Health; Surgery ; Oncology ; Surgical Oncology
ISSN
1068-9265
eISSN
1534-4681
DOI
10.1245/s10434-007-9474-9
pmid
17574500
Publisher site
See Article on Publisher Site

Abstract

Annals of Surgical Oncology 14(9):2437–2439 DOI: 10.1245/s10434-007-9474-9 Melanomas Can Completion Lymph Node Dissection Be Avoided for a Positive Sentinel Node in Melanoma? 1 1 2 Donald L. Morton, MD, Randall P. Scheri, MD, and Charles M. Balch, MD John Wayne Cancer Institute, Saint Johns Health Center, Santa Monica, CA, USA Johns Hopkins Medical Institutions, Baltimore, MD, USA Sentinel node biopsy (SNB) in melanoma was with hematoxyin and eosin (H&E) and with immu- developed as a minimally invasive technique to nohistochemistry using antibodies to S-100 and identify the 20% of patients who have occult lymph HMB-45. NSNs were bivalved and examined only by node metastases and therefore could benefit from H&E, which probably led to underestimation of the completion lymph node dissection (CLND). Recently incidence of NSN metastasis. Data on patient published interim results from the first Multicenter demographics and primary tumor pathological fea- Selective Lymphadenectomy Trial (MSLT-I) have tures were collected, and the SNs were microana- validated the accuracy and reliability of SNB in tomically staged for zone of metastatic involvement, 1,2 melanoma. Interestingly, results revealed that number of tumor-involved zones, size of metastases, nearly 80–90% of patients who underwent CLND and number of metastatic foci. Of 127 patients

Journal

Annals of Surgical Oncology – Springer Journals

Published: Jun 17, 2007

There are no references for this article.